HomeCompareVBIV vs SBUX

VBIV vs SBUX: Dividend Comparison 2026

VBIV yields 3062.79% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VBIV wins by $553925093173.65M in total portfolio value
10 years
VBIV
VBIV
● Live price
3062.79%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$553925093173.82M
Annual income
$520,495,004,530,333,300.00
Full VBIV calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — VBIV vs SBUX

📍 VBIV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVBIVSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VBIV + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VBIV pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VBIV
Annual income on $10K today (after 15% tax)
$260,336.91/yr
After 10yr DRIP, annual income (after tax)
$442,420,753,850,783,300.00/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, VBIV beats the other by $442,420,753,850,722,800.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VBIV + SBUX for your $10,000?

VBIV: 50%SBUX: 50%
100% SBUX50/50100% VBIV
Portfolio after 10yr
$276962546586.99M
Annual income
$260,247,502,265,202,240.00/yr
Blended yield
93.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

VBIV
Analyst Ratings
6
Buy
Consensus: Buy
Altman Z
-14.9
Piotroski
4/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VBIV buys
0
SBUX buys
0
No recent congressional trades found for VBIV or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVBIVSBUX
Forward yield3062.79%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$553925093173.82M$167.0K
Annual income after 10y$520,495,004,530,333,300.00$71,136.45
Total dividends collected$551616311074.85M$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: VBIV vs SBUX ($10,000, DRIP)

YearVBIV PortfolioVBIV Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$316,979$306,278.71$11,121$420.68+$305.9KVBIV
2$9,412,423$9,073,255.39$12,548$648.40+$9.40MVBIV
3$261,868,365$251,797,073.09$14,440$1,013.98+$261.85MVBIV
4$6,827,292,278$6,547,093,127.32$17,068$1,617.30+$6827.28MVBIV
5$166,830,733,833$159,525,531,095.41$20,912$2,649.52+$166830.71MVBIV
6$3,821,633,158,895$3,643,124,273,693.35$26,875$4,499.29+$3821633.13MVBIV
7$82,083,497,792,692$77,994,350,312,674.64$36,771$8,014.12+$82083497.76MVBIV
8$1,653,448,854,533,535$1,565,619,511,895,354.20$54,542$15,197.11+$1653448854.48MVBIV
9$31,243,073,498,582,136$29,473,883,224,231,256.00$89,602$31,242.49+$31243073498.49MVBIV
10$553,925,093,173,816,260$520,495,004,530,333,300.00$167,011$71,136.45+$553925093173.65MVBIV

VBIV vs SBUX: Complete Analysis 2026

VBIVStock

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

Full VBIV Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this VBIV vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VBIV vs SCHDVBIV vs JEPIVBIV vs OVBIV vs KOVBIV vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.